Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ( 131 I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer. Patients and Methods: Patients with thyroid cancer of any histology that was resistant or not appropriate for 131 I were enrolled onto a single-arm phase II trial to receive axitinib orally (starting dose, 5 mg twice daily). Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors was the primary end point. Secondary end points included duration of response, progression-free survival (PFS), overall survival, safety, and modulation of soluble (s) VEGFR. Results: Sixty patients were enrolled. Partial responses were observed in 18 patients, yielding an ORR of 30% (95% CI, 18.9 to 43.2). Stable disease lasting ≥ 16 weeks was reported in another 23 patients (38%). Objective responses were noted in all histologic subtypes. Median PFS was 18.1 months (95% CI, 12.1 to not estimable). Axitinib was generally well tolerated, with the most common grade ≥ 3 treatment-related adverse event being hypertension (n = 7; 12%). Eight patients (13%) discontinued treatment because of adverse events. Axitinib selectively decreased sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT, demonstrating its targeting of VEGFR. Conclusion: Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Sherma, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12488-9 · Cited by 925
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Self-citationGilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Self-citation
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Self-citationThyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Hu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G. R., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, E. Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 635
Self-citationProgress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Self-citationPhase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Smallridge, R. C., & Copland, J. A. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.013 · Cited by 481
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 414
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Self-citationPhase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Lam, E. T., Ringel, M. D., Kloos, R. T., Prior, T. W., Knopp, M. V., Liang, J., Sammet, S., Hall, N. C., Wakely, P. E., Vasko, V. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0068 · Cited by 377
Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq190 · Cited by 350
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7815 · Cited by 340
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Wells, S. A., Pacini, F., Robinson, B. G., & Santoro, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1204 · Cited by 338
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Izzedine, H., Massard, C., Spano, J. P., Goldwasser, F., Khayat, D., & Soria, J. C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.001 · Cited by 332
Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Nagaiah, G., Hossain, A., Mooney, C. J., Parmentier, J., & Remick, S. C. (2011) · Journal of Oncology · doi:10.1155/2011/542358 · Cited by 317
New developments in the diagnosis and treatment of thyroid cancer
Schneider, D. F., & Chen, H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21195 · Cited by 316
Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2134 · Cited by 293
Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J., & Haddad, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2461 · Cited by 257
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Capdevila, J., & Stjepanovic, N. (2014) · Biologics: Targets and Therapy · doi:10.2147/btt.s39381 · Cited by 85
Antonelli, A., Bocci, G., La Motta, C., Ferrari, S. M., Fallahi, P., Fioravanti, A., Sartini, S., Minuto, M., Piaggi, S., Corti, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1905 · Cited by 66
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
“Eight pts (13%) withdrew axitinib because of AE [100].”
Background
Metadata
- Authors
- Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., Tortorici, M., Shalinsky, D. R., Liau, K. F., & Cohen, R. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-10
- Volume
- 26
- Issue
- 29
- Pages
- 4708-4713
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106695112
- Cited by
- 623
- References
- 24
- FWCI
- 40.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.